Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE: GKOS ) reported successful topline outcomes from its latest Phase 4 clinical study. The trial evaluated the effectiveness of administering the company’s iDose TR therapy alongside traditional cataract surgery. Researchers compared this com